Business
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmac
About this update from Collegium Pharmaceutical, Inc.
[{"type":"image","alt":"Collegium Pharmaceutical, Inc.","displaySize":"","headline":null,"caption":"Collegium Pharmaceutical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S5ES9Zc2Z2psQENPovttBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/d00262a0b75d92cc28a42bcc16d20a1a","width":300,"height":100}},"lazy":false},{"type":"text","content":"STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.","length":351,"tagName":"p"},{"type":"text","content":"Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.","length":426,"tagName":"p"},{"type":"text","content":"About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by JORNAY PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with JORNAY PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.","length":684,"tagName":"p"},{"type":"text","content":"Investor Contacts:Ian KarpHead of Investor [email protected]","length":77,"tagName":"p"},{"type":"text","content":"Danielle JesseDirector, Investor [email protected]","len...